

Syncona Update

May 2021





Syncona

Building the next generation of healthcare companies

Key Announcements

[Notice of Final Results](#)

18.05.21

Syncona will announce its final results for the year ended 31 March 2021 on 17 Thursday June 2021. Syncona will host a webcast and conference call the same day at 9.00am BST. The webcast will be available on the Company's website.

Key Media Coverage

[Despite those amazing jabs, big pharma shares are ailing - experts say it may be time to get a profit booster - by investing in drug firms](#)

Mail on Sunday 09.05.21

Rosie Murray-West of the Mail on Sunday highlighted Syncona to potential investors as a good way to get exposure to a diversified portfolio of exciting biotech companies.

[Kenneth Galbraith joins Syncona as executive in residence](#)

PharmaTimes 11.05.21

PharmaTimes covered April's appointment of Kenneth Galbraith as Executive in Residence at Syncona. In this role, Kenneth will work alongside the Syncona team to support portfolio companies as they scale and develop, pulling on 30 years' experience as a life sciences executive, director, investor and advisor across North America.

Achilles Therapeutics

Developing novel cancer immunotherapies targeting clonal neoantigens

Key Announcements

[Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board](#)

03.05.21

Achilles announced the appointment of Julie O'Neill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board. Both individuals come to Achilles with strong track records of experience in cell therapy and cell therapy manufacturing. The company has also expanded its Scientific Advisory Board with the addition of Dr. Velders.

[Achilles Corporate Presentation – May 2021](#)

04.05.21

Achilles uploaded an updated corporate presentation for May which can be found [here](#).

[Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference](#)

05.05.21

Achilles announced that Iraj Ali, Chief Executive Officer, would participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on 13 May 2021. The replay can be found [here](#).

[Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium](#)

06.05.21

Achilles announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumour neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.

[Achilles reports First Quarter 2021 Financial Results](#)

11.05.21

Achilles reports first quarter 2021 financial results and recent business highlights including the first clinical data from the ongoing CHIRON and THETIS trials evaluating TIL cNeT therapy in patients with non-small cell lung cancer and melanoma to the successful US IPO on NASDAQ.

Key Media Coverage

[O'Neill brings Achilles to heel](#)

The Sunday Times 09.05.21

Nick Webb of The Sunday Times reports that following the NASDAQ flotation of Achilles that raised \$175.5m for the cancer-focused biotech, Achilles has just tapped up former Gilead and Alexion executive Julie O'Neill to give its board a more heavyweight pharma look. Since leaving Alexion, where she ran its global manufacturing operations, O'Neill has taken interesting gigs including independent non-executive roles at John Climax and Ronan Lambe's clinical research group Icon, the allergy-focused French biotech DBV Technologies, and immuno-oncology outfit Hookipa Pharma.

Autolus Therapeutics

Developing next generation programmed T cell therapies for the treatment of cancer

Key Announcements

[Autolus reports Q1 2021 Financial Results](#)

06.05.21

Autolus announced its operational and financial results for the quarter ended 31 March 2021. Dr. Christian Itin, Chief Executive Officer said, "We have had a productive first quarter and are on track for multiple clinical read outs during the remainder of this year and into 2022."

[Autolus to present additional data in AUTO1 in IBCL](#)

12.05.21

Autolus announced an abstract presentation related to AUTO1 in relapsed / refractory indolent B cell lymphomas (IBCL) at the European Hematology Association (EHA) Virtual Congress to be held 9-17 June, 2021.

[Autolus Notice of Annual General Meeting \(AGM\) on Friday, June 18, 2021](#)

21.05.21

Autolus posted notice of its Annual General Meeting (AGM) to shareholders. The Notice states that the AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Friday, June 18, 2021. Attendance in person is not permitted.

[Autolus Therapeutics Announces an Additional Nature Publication for AUTO1](#)

25.05.21

Autolus announced a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia (ALL) patients treated with AUTO1. Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells.

Key Media Coverage

[Autolus' CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS in small lymphoma trial](#)

FierceBiotech 13.05.21

Nick Paul Taylor of FierceBiotech writes that Autolus linked its CD19 CAR-T to a 100% complete response rate in a small indolent B-cell lymphoma trial. AUTO1 drove the responses without causing any grade 3 or worse cytokine release syndrome, sending shares in the biotech up 35%. It is still early days for the trial and the sample size is small but the available data offer encouragement.

Freeline Therapeutics

Focused on developing curative gene therapies for chronic systemic diseases

Key Announcements

[Freeline Presents Data Highlighting Platform Technology at the American Society of Gene and Cell Therapy Annual Meeting 2021](#)

11.05.21

Freeline presented six posters detailing research data from its proprietary gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2021, taking place 11-14 May 2021. "These data presented today at ASGCT highlight the strong scientific foundation that underlies our gene therapy programs and broader technology platform," said Theresa Heggie, Chief Executive Officer.

[Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference](#)

12.05.21

Freeline announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on 18 May 2021 at 4:50pm EST. Senior management will also participate in virtual one-on-one meetings with investors at the conference. A webcast of the event is available on the [Investors](#) section of the Freeline website.

[Freeline Reports First Quarter Financial Results](#)

18.05.21

Freeline reported financial results for the first quarter of 2021 and provided an update on recent business highlights. The report highlights that the FLT190 phase 1/2 dose-finding study in Fabry disease is on track to dose additional patients, with data to be presented by year-end. Additionally, the FLT201 phase 1/2 dose-finding study in Gaucher disease Type 1 is expected to be in the clinic by the year-end and the FLT180a phase 1/2 dose-confirmation study in haemophilia B is on track to initiate trial sites by year-end.

Gyroscope Therapeutics

Developing gene therapies and surgical delivery systems for retinal diseases

Key Announcements

[Update on Gyroscope Therapeutics' proposed IPO in the United States](#)

04.05.21

Gyroscope filed an amended registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering in the United States of its American Depositary Shares. The registration statement disclosed an indicative pricing range for the proposed offering of U.S. \$20.00 - \$22.00 per ADS, which at the midpoint would result in gross proceeds of \$141.8m.

[Gyroscope Therapeutics update on proposed IPO](#)

07.05.21

Gyroscope postponed plans for its initial public offering in light of the current market conditions. Khurem Farooq, Gyroscope Chief Executive said, "Based on the positive feedback we have received from institutional investors on the strength of our science and investigational gene therapies, we believe it's in the best interest of our existing shareholders and employees to execute our IPO in more favourable market conditions. In the meantime, we are continuing to advance our clinical program for our investigational gene therapy, GT005, and our earlier stage pipeline."

Key Media Coverage

[A look at aftermarket performance for 2021's NASDAQ IPO class: Data Byte](#)

07.05.21

Paul Bonanos of BioCentury analysed aftermarket performance for NASDAQ IPOs following Gyroscope's postponement and a withdrawal from Centrexion Therapeutics. The companies' choices to pull back come at a time when the pace of new listings may be slowing down. A variety of factors have contributed to a downturn among biotech indexes this month; the SPDR S&P Biotech ETF (XBI), for one, had dropped at least 1% in each session from its close 28 April at 139.69 until 6 May's close of 125.69, shedding 11% across that span.

Neogene Therapeutics

Pioneering the development of next-generation, fully personalized engineered T cells therapies for a broad spectrum of cancers

Key Announcements

[Neogene Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Operating Officer](#)
26.05.2021

Neogene announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Operating Officer. Dr. Pfeiffenberger will oversee Neogene's business operations and will be based out of Neogene's new U.S. headquarters in Santa Monica. He most recently served as senior vice president, U.S. Oncology, at Bristol Myers Squibb and brings an industry-leading track record in oncology and general management.

Key Media Coverage

[Next-gen T-cell player Neogene bolsters U.S. team, adding Bristol Myers vet as COO](#)
FierceBiotech 26.05.2021

Amirah Al Idrus of FierceBiotech writes that Brent Pfeiffenberger is taking his experience from Bristol Myers Squibb into the biotech world as the as Chief Operating Officer of Neogene Therapeutics, a transatlantic biotech working on next-generation T-cell therapies.